Table 4.
Correlation between protein expression and stage progression in 118 cases of high grade non-muscle invasive bladder cancer
| Variables | Cases without progression | Cases with progression | P-value | |
|---|---|---|---|---|
| P53 | Low | 74 (76.3) | 12 (70.6) | 0.760 |
| High | 23 (23.7) | 5 (29.4) | ||
| Nuclear p27 | Low | 84 (90.3) | 12 (70.6) | 0.040 |
| High | 9 (9.7) | 5 (29.4) | ||
| Cytoplasmic p27 | Low | 85 (91.4) | 15 (88.2) | 0.651 |
| High | 8 (8.6) | 2 (11.8) | ||
| Androgen receptor | Low | 86 (89.6) | 15 (88.2) | > 0.999 |
| High | 10 (10.4) | 2 (11.8) | ||
| E2F1 | Low | 64 (65.3) | 5 (29.4) | 0.007 |
| High | 34 (34.7) | 12 (70.6) | ||
| EZH2 | Low | 87 (90.6) | 15 (88.2) | 0.670 |
| High | 9 (9.4) | 2 (11.8) | ||
| Nuclear survivin | Low | 55 (57.9) | 10 (55.6) | > 0.999 |
| High | 40 (42.1) | 8 (44.4) | ||
| Cytoplasmic survivin | Low | 85 (89.5) | 14 (77.8) | 0.234 |
| High | 10 (10.5) | 4 (22.2) | ||
| IMP3 | Low | 93 (94.9) | 15 (88.2) | 0.276 |
| High | 5 (5.1) | 2 (11.8) | ||
| FASN | Low | 46 (46.0) | 5 (27.8) | 0.199 |
| High | 54 (54.0) | 13 (72.2) | ||
| TSC1/Hamartin | Low | 86 (87.8) | 12 (70.6) | 0.130 |
| High | 12 (12.2) | 5 (29.4) | ||
| MAGEA4 | Low | 29 (30.9) | 2 (11.8) | 0.145 |
| High | 65 (69.1) | 15 (88.2) | ||
| NY-ESO-1 | Low | 96 (97.0) | 100 (100) | > 0.999 |
| High | 3 (3.0) | 0 (0) | ||
| 14-3-3σ | Low | 41 (42.7) | 6 (35.3) | 0.606 |
| High | 55 (57.3) | 11 (64.7) |